Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Cardiology
•
Preventive Cardiology
How do you factor in a positive family history of premature CAD into ASCVD risk estimation?
Do you use other risk prediction calculators instead?
Related Questions
What is your typical approach to the use of beta blockers in the setting of recent cocaine use amongst patients presenting with cocaine-related MI, arrhythmias, or new-onset heart failure?
Do you recommend noninvasive testing or coronary angiography as the initial test for pre-kidney transplant evaluation of an asymptomatic patient older than 50 years of age with ESKD secondary to diabetic nephropathy and no known history of CAD?
When would you consider adding an SGLT2 inhibitor, MRA, and/or ARNI (in lieu of ACE inhibitor or ARB) when discharging patients following revascularization for acute MI with newly reduced LV systolic function?
How do you decide between ordering coronary calcium scoring versus coronary CTA in asymptomatic patients with low to moderate risk for CAD?
Would you consider opting for beta blocker withdrawal to improve exercise capacity in patients with heart failure with preserved ejection fraction and chronotropic incompetence?
Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?
With the recent trials such as SELECT and STEP-HFpEF demonstrating benefits of GLP1-agonists in terms of CV risk reduction and improved exercise function, have you begun to incorporate this class of medications into routine CV health maintenance for patients with HFpEF and/or pre-existing CAD?
If prompted as an outpatient, how do you counsel patients on the rare cardiac complications of vaccinations including myocarditis?
What are your top takeaways from ACC 2024?
How frequently do you obtain lipoprotein (a) levels on asymptomatic patients without a prior history of CAD?